BMI-1
抑制剂选择性比较
BMI-1产品
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S7372 |
PTC-209PTC-209是一种有效的选择性BMI-1抑制剂，在HEK293T细胞系中IC50为0.5 μM，并导致癌症起始细胞(CICs)的不可逆减少。 |
Immunoblot analysis of BMI-1 and H2AK119Ub levels following 72 h treatment with 10 µM PTC-209. β-actin and total H2A served as loading controls.
|
|
| S8820 |
Unesbulin (PTC596)Unesbulin (PTC596)是第二代BMI-1抑制剂，可加速BMI-1的降解。PTC596 可下调 MCL-1 并诱导p53依赖性的线粒体的凋亡。处理套细胞淋巴瘤细胞72小时，IC50为68-340 nM。 |
||
| S5315 |
PRT4165PRT4165 is a Bmi1/Ring1A inhibitor with an IC50 of 3.9 µM in the cell-free assay and also inhibits PRC1-mediated H2A ubiquitylation in vivo and in vitro. |
||
| S7539 |
PTC-209 HBrPTC-209 HBr 是PTC-209的氢溴酸盐 , 这是一种强效的选择性的BMI-1抑制剂，其IC50为0.5 μM, 可以不可逆的减少癌起始细胞(CICs)。 |
b Reduced viability 96 h post treatment was observed in all MM cell lines in a dose-dependent manner, but not in BMSCs or PBMCs (c). d Downregulation of CCND1 and MYC as well as upregulation of CDNK1A and CDKN1B was noted 5 h post treatment. e Deregulation of proliferation-associated genes translated into a significant increase of cells in the G1 phase and concurrent decrease in the S and G2M phase of the cell cycle 24 h post treatment. ***P < 0.001, **P < 0.01 and *P < 0.05 vs DMSO control
|
|
| S8662 |
PTC-028PTC-028是一种具有生物口服活性的化合物，能够通过翻译后修饰减少BMI-1水平。 |
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S7372 |
PTC-209PTC-209是一种有效的选择性BMI-1抑制剂，在HEK293T细胞系中IC50为0.5 μM，并导致癌症起始细胞(CICs)的不可逆减少。 |
Immunoblot analysis of BMI-1 and H2AK119Ub levels following 72 h treatment with 10 µM PTC-209. β-actin and total H2A served as loading controls.
|
|
| S8820 |
Unesbulin (PTC596)Unesbulin (PTC596)是第二代BMI-1抑制剂，可加速BMI-1的降解。PTC596 可下调 MCL-1 并诱导p53依赖性的线粒体的凋亡。处理套细胞淋巴瘤细胞72小时，IC50为68-340 nM。 |
||
| S5315 |
PRT4165PRT4165 is a Bmi1/Ring1A inhibitor with an IC50 of 3.9 µM in the cell-free assay and also inhibits PRC1-mediated H2A ubiquitylation in vivo and in vitro. |
||
| S7539 |
PTC-209 HBrPTC-209 HBr 是PTC-209的氢溴酸盐 , 这是一种强效的选择性的BMI-1抑制剂，其IC50为0.5 μM, 可以不可逆的减少癌起始细胞(CICs)。 |
b Reduced viability 96 h post treatment was observed in all MM cell lines in a dose-dependent manner, but not in BMSCs or PBMCs (c). d Downregulation of CCND1 and MYC as well as upregulation of CDNK1A and CDKN1B was noted 5 h post treatment. e Deregulation of proliferation-associated genes translated into a significant increase of cells in the G1 phase and concurrent decrease in the S and G2M phase of the cell cycle 24 h post treatment. ***P < 0.001, **P < 0.01 and *P < 0.05 vs DMSO control
|
|
| S8662 |
PTC-028PTC-028是一种具有生物口服活性的化合物，能够通过翻译后修饰减少BMI-1水平。 |
沪公网安备 31011502012800号